Topic:Crohn disease in adults
Induction and maintenance therapy with ustekinumab improves clinical response and remission for up to 52 weeks in patients with moderately-to-severely active Crohn disease resistant to tumor necrosis factor antagonists or conventional therapy (N Engl J Med 2016 Nov 17)
To access full text you may have to log in to your NHS Athens account (click here to register for free). If full text is not available then please email us to request a copy.
